

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 6, 2019**

OCULAR THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36554
(Commission
File Number)

20-5560161
(IRS Employer
Identification No.)

**15 Crosby Drive
Bedford, MA 01730**
(Address of Principal Executive Offices) (Zip Code)

Company's telephone number, including area code: **(781) 357-4000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of exchange on which registered</u>
Common Stock, \$0.0001 par value per share	OCUL	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01. Other Events.

On June 6, 2019, Ocular Therapeutix, Inc. (the “Company”) will be attending the Jefferies 2019 Global Healthcare Conference and presenting data from the Company’s first pivotal Phase 3 clinical trial of OTX-TP, an intracanalicular insert that delivers a preservative-free formulation of the drug travoprost for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The Company previously announced topline results from this Phase 3 clinical trial on May 20, 2019. Excerpts from the presentation containing the data from the Phase 3 clinical trial are included in Exhibit 99.1 attached hereto and are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Excerpts from Company presentation, dated June 6, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OCULAR THERAPEUTIX, INC.

Date: June 6, 2019

By: /s/ Donald Notman
Donald Notman
Chief Financial Officer

OTX-TP PHASE 3 TRIAL: TOPLINE EFFICACY RESULTS

MEAN INTRAOCULAR PRESSURE

Diurnal Timepoints	2 Weeks			6 Weeks			12 Weeks		
	OTX-TP mm Hg	Placebo mm Hg	LS Mean P-value	OTX-TP mm Hg	Placebo mm Hg	LS Mean P-value	OTX-TP mm Hg	Placebo mm Hg	LS Mean P-value
8:00 AM	21.02	22.86	<.0001	21.93	22.73	0.0181	22.83	23.23	0.2521
10:00 AM	20.16	21.92	<.0001	21.05	21.85	0.0077	21.74	22.45	0.0234
4:00 PM	19.46	21.51	<.0001	20.53	21.55	0.0004	21.41	22.08	0.0310

Full Analysis Set, Baseline-adjusted Least Squared (LS) Means



OTX-TP PHASE 3 TRIAL: TOPLINE EFFICACY RESULTS

REDUCTION IN INTRAOCULAR PRESSURE (CHANGE FROM BASELINE)

Diurnal Timepoints	2 Weeks			6 Weeks			12 Weeks		
	OTX-TP mm Hg	Placebo mm Hg	LS Mean P-value	OTX-TP mm Hg	Placebo mm Hg	LS Mean P-value	OTX-TP mm Hg	Placebo mm Hg	LS Mean P-value
8:00 AM	-5.72	-3.88	<.0001	-4.81	-4.01	0.0181	-3.91	-3.52	0.2521
10:00 AM	-4.92	-3.16	<.0001	-4.03	-3.23	0.0077	-3.34	-2.63	0.0234
4:00 PM	-5.22	-3.18	<.0001	-4.16	-3.14	0.0004	-3.27	-2.60	0.0310

Full Analysis Set, Baseline-adjusted Least Squared (LS) Means

